This infrastructure includes increased access to MRI and PET facilities, laboratory facilities to analyze CSF for Alzheimer’s disease biomarkers and testing blood APOE [37]. The gene discussed is APOE; the disease is early-onset autosomal dominant Alzheimer disease.